MARKET

XTLB

XTLB

X T L Bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.750
+0.860
+29.76%
Pre Market: 3.470 -0.28 -7.47% 08:43 03/08 EST
OPEN
4.820
PREV CLOSE
2.890
HIGH
6.11
LOW
3.095
VOLUME
33.10K
TURNOVER
--
52 WEEK HIGH
6.11
52 WEEK LOW
0.6250
MARKET CAP
19.28M
P/E (TTM)
-6.9444
1D
5D
1M
3M
1Y
5Y
SIFY, WTI, OPEN and EVFM among notable midday movers
Gainers: Second Sight Medical Products (EYES) +337%.AMTD International (HKIB) +27%.Sify Technologies Limited (SIFY) +26%.Boqii Holding Limited (BQ) +25%.ChromaDex Corporation (CDXC) +22%.W&T Offshore (WTI) +21%.Anchiano Therapeutics (ANCN) +18%.Purple Inno...
Seekingalpha · 2d ago
Second Sight Medical Products, XTL Biopharmaceuticals leads healthcare gainers; Evofem Biosciences, T2 Biosystems among major losers
Gainers: Second Sight Medical Products (EYES) +151%, XTL Biopharmaceuticals (XTLB) +42%, Nurix Therapeutics (NRIX) +9%, Auris Medical Holding (EARS) +5%, Anchiano Therapeutics (ANCN) +5%.Losers: Evofem Biosciences (EVFM) -34%, T2 Biosystems (TTOO) -25%, IM...
Seekingalpha · 2d ago
Mid-Morning Market Update: Markets Mixed; Big Lots Earnings Top Views
Following the market opening Friday, the Dow traded up 0.32% to 31,024.11 while the NASDAQ fell 0.5% to 12,659.24. The S&P also rose, gaining 0.09% to 3,771.85.
Benzinga · 2d ago
MRO, FLGT, VET and CPE among premarket gainers
XTL Biopharmaceuticals (XTLB) +93%.Second Sight Medical Products (EYES) +50%.Fulgent Genetics (FLGT +32% on Q4 results.CLPS Incorporation (CLPS +29% on FQ2 results.Sify Technologies Limited (SIFY +26% on report of Blackstone buying minority stake.Waitr Hol...
Seekingalpha · 3d ago
The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 13)
Benzinga · 01/14 12:56
The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 12)
Benzinga · 01/13 12:25
The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 29)
Benzinga · 12/30/2020 13:08
The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28)
Benzinga · 12/29/2020 13:09
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XTLB. Analyze the recent business situations of X T L Bio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
Institutional Holdings
Institutions: 6
Institutional Holdings: 500.09K
% Owned: 9.73%
Shares Outstanding: 5.14M
TypeInstitutionsShares
Increased
1
9.39K
New
2
18.50K
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Director
Shlomo Shalev Spokone
Chairman/Director
Shlomo Shalev
Chief Executive Officer
Joshua Levine
Deputy Chief Executive Officer/Chief Financial Officer
Ronen Twito
Other
Moshe Mittelman
Director
Daphna Paran
Director
Alexander Rabinovich
Director
Alexander Rabinovitch
Non-Executive Director
Dafna Cohen
Non-Executive Director
Jaron Diament
No Data
About XTLB
XTL Biopharmaceuticals Ltd., incorporated on March 9, 1993, is a biopharmaceutical company. The Company is engaged in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The Company’s developed drug candidate is hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren’s syndrome (SS). Its hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE). hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. Its rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM).

Webull offers kinds of X T L Biopharmaceuticals Ltd (ADR) stock information, including NASDAQ:XTLB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XTLB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XTLB stock methods without spending real money on the virtual paper trading platform.